Viking Therapeutics Inc. (VKTX)

14.20
0.26 1.80
NASDAQ : Health Technology
Prev Close 14.46
Open 14.28
Day Low/High 13.87 / 14.53
52 Wk Low/High 2.00 / 24.00
Volume 2.44M
Avg Volume 3.78M
Exchange NASDAQ
Shares Outstanding 70.15M
Market Cap 973.02M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected For Oral Late-Breaker Presentation At The Liver Meeting® 2018

Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected For Oral Late-Breaker Presentation At The Liver Meeting® 2018

Presentation to Highlight Positive 12-Week Data for Novel, Liver-Selective Thyroid Receptor Beta Agonist in Patients with Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol

There's Nothing Very Attractive About GE

There's Nothing Very Attractive About GE

It's an interesting story but there are better places for your funds.

Viking Therapeutics Presents Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture In Plenary Oral Presentation At ASBMR 2018 Annual Meeting

Viking Therapeutics Presents Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture In Plenary Oral Presentation At ASBMR 2018 Annual Meeting

Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose-Dependent Increases in Lean Body Mass Ranging from 4.8% to 9.1% Following Treatment with VK5211

Viking Therapeutics To Participate In Upcoming Investor Conferences

Viking Therapeutics To Participate In Upcoming Investor Conferences

SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

Viking Therapeutics Announces Pricing Of $175.8 Million Public Offering Of Common Stock

Viking Therapeutics Announces Pricing Of $175.8 Million Public Offering Of Common Stock

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

Viking Therapeutics Announces Proposed Public Offering Of Common Stock

Viking Therapeutics Announces Proposed Public Offering Of Common Stock

SAN DIEGO, Sept. 19, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

FedEx's Report Was Soft, but the Guidance Isn't Bad

FedEx's Report Was Soft, but the Guidance Isn't Bad

It is likely that value buyers will be looking for entry soon as the stock tests the $240 area.

Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) And Elevated LDL-Cholesterol

Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK2809 In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) And Elevated LDL-Cholesterol

Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in LDL-C in Patients Receiving VK2809

Six Biotechnology Names on My Watch List

Six Biotechnology Names on My Watch List

After recent weakness in the biotech sector, here are some names to start watching.

Insiders Buy The Holdings Of WMCR ETF

Insiders Buy The Holdings Of WMCR ETF

A look at the weighted underlying holdings of the Invesco Wilshire Micro-Cap ETF (WMCR) shows an impressive 19.0% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying » Viking Therapeutics Inc , which makes up 0.55% of the Invesco Wilshire Micro-Cap ETF (WMCR), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data.

A Lesson to Learn From Thursday's Market Action

A Lesson to Learn From Thursday's Market Action

You don't have to be Sigmund Freud to understand the psychology here.

Viking Therapeutics To Participate In Upcoming Investor Conferences

Viking Therapeutics To Participate In Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2018 /PRNewswire/ -- Viking Therapeutics, Inc.

VKTX: Insiders Vs. Shorts

VKTX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 08/15/2018 settlement date, and Viking Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 7.55 "days to cover" versus the median component at 5.05. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Viking Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update

Viking Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

Viking Therapeutics To Report Financial Results For Second Quarter 2018 On August 9, 2018

Viking Therapeutics To Report Financial Results For Second Quarter 2018 On August 9, 2018

Conference Call Scheduled for Thursday, August 9 at 4:30 p.m. Eastern Time

Insiders Bullish On Certain Holdings Of WMCR

Insiders Bullish On Certain Holdings Of WMCR

A look at the weighted underlying holdings of the Invesco Wilshire Micro-Cap ETF (WMCR) shows an impressive 18.1% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying » Viking Therapeutics Inc , which makes up 0.50% of the Invesco Wilshire Micro-Cap ETF (WMCR), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data.

Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected For Plenary Oral Presentation At ASBMR 2018 Annual Meeting

Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected For Plenary Oral Presentation At ASBMR 2018 Annual Meeting

Presentation to Highlight Data for Novel, Orally Available SARM in Patients Recovering from Hip Fracture Surgery

Overall the Market Is in Good Shape

Overall the Market Is in Good Shape

The action started a little slowly this morning but market players shook off early jitters and are doing a nice job of building on yesterday's momentum.

First Week Of VKTX February 2019 Options Trading

First Week Of VKTX February 2019 Options Trading

Investors in Viking Therapeutics Inc saw new options become available this week, for the February 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Viking Therapeutics Announces Closing Of Public Offering Of Common Stock

Viking Therapeutics Announces Closing Of Public Offering Of Common Stock

SAN DIEGO, June 12, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of...

Viking Therapeutics Announces Pricing Of $67.5 Million Public Offering Of Common Stock

Viking Therapeutics Announces Pricing Of $67.5 Million Public Offering Of Common Stock

SAN DIEGO, June 7, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its...

Viking Therapeutics Announces Proposed Public Offering Of Common Stock

Viking Therapeutics Announces Proposed Public Offering Of Common Stock

SAN DIEGO, June 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to...

Interesting VKTX Put And Call Options For January 2020

Interesting VKTX Put And Call Options For January 2020

Investors in Viking Therapeutics Inc saw new options become available today, for the January 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 590 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

There Is Still a Strong Appetite for Big Moving Speculative Names

There Is Still a Strong Appetite for Big Moving Speculative Names

There isn't any big mystery about what is going on here.

VKTX Crosses Above Average Analyst Target

VKTX Crosses Above Average Analyst Target

In recent trading, shares of Viking Therapeutics Inc have crossed above the average analyst 12-month target price of $9.88, changing hands for $9.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

First Week Of VKTX July 20th Options Trading

Investors in Viking Therapeutics Inc saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VKTX options chain for the new July 20th contracts and identified the following call contract of particular interest.

Viking Therapeutics To Report Financial Results For First Quarter 2018 On May 9, 2018

Conference Call Scheduled for Wednesday, May 9 at 4:30 p.m. Eastern Time